Building a healthcare buzz
Lydia WorthingtonHealthcare, BuzzMetrics, United States
EXECUTIVE SUMMARY
Building even a small amount of buzz before a product is launched can have a vast, positive impact on the amount of discussion a product merits after it has been released. To test this theory, BuzzMetrics collected word-of-mouth discussion data on two sets of new drugs: the oncology therapies Abraxane and Tarceva, and the treatments for chronic illnesses Tysabri and Byetta.
Through our proprietary analytic methodology and software, we collected buzz among relevant online patient and caregiver forums for each therapeutic category. We tracked the level of discussion...